Who is sponsoring NCT03542006?

NCT03542006 is sponsored by Tel-Aviv Sourasky Medical Center.

What drugs are being tested in NCT03542006?

Interventions in NCT03542006: Brinzolamide Ophthalmic.

What condition does NCT03542006 study?

NCT03542006 studies Central Serous Chorioretinopathy.

Is NCT03542006 still recruiting?

NCT03542006 is currently status unknown. Last updated 31 May 2018.

Last reviewed 2018-05-31 · How we verify

NCT03542006

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy

Status unknown Phase 2 Last updated 31 May 2018

What this trial tests

Phase 2 trial testing Brinzolamide Ophthalmic in Central Serous Chorioretinopathy in 35 participants. Status unknown.

Timeline

1 June 2018

Primary endpoint
1 January 2019

1 April 2019

Quick facts

Lead sponsor	Tel-Aviv Sourasky Medical Center
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	35
Start date	1 June 2018
Primary completion	1 January 2019
Estimated completion	1 April 2019
Sites	2 locations across Argentina, Israel

Drugs / interventions tested

Brinzolamide Ophthalmic

Conditions studied

Central Serous Chorioretinopathy — all drugs for Central Serous Chorioretinopathy →

Sponsor

Tel-Aviv Sourasky Medical Center

Who can join

Adults 18 to 60, any sex, with Central Serous Chorioretinopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Examine the efficacy of brinzolamide for the treatment of central serous chorioretinopathy

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Central Serous Chorioretinopathy

Currently open trials in the same condition.

NCT06527326 — the Study of the Association Between the Gut Microbiota and Central Serous Chorioretinopathy · NA · recruiting
NCT06346405 — Central Serous Chorioretinopathy and Micropulse Laser Treatment · recruiting
NCT05570591 — Subthreshold Nanosecond Laser for Non-resolving Central Serous Chorioretinopathy · NA · recruiting
NCT05589974 — Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy · recruiting

Other Tel-Aviv Sourasky Medical Center trials

Trials by the same sponsor.

NCT07380737 — Feasibility and Preliminary Effects of the Walking Tall App for Home-Based Gait Training in Parkinson's Disease: A Pilot · NA · recruiting
NCT07104136 — Improving Adherence to COPD Treatments in Primary Care · NA · enrolling by invitation
NCT07327021 — MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC · Phase 2 · recruiting
NCT07191249 — A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previousl · Phase 2 · not yet recruiting
NCT07235332 — Assessing Toxic Metal Exposure From Vegetarian/Vegan, Omnivorous, and Low-carb Diets in Israel. · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03542006 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tel-Aviv Sourasky Medical Center
Last refreshed: 31 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03542006.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing